



Sally Arai

Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICES

- **Blood and Marrow Transplant Program**

300 Pasteur Dr Rm H0101

MC 5623

Stanford, CA 94305

Tel (650) 723-0822 **Fax** (650) 725-8950

Bio

BIO

Dr. Arai has formal training in clinical research with a Masters in Epidemiology from Stanford University. She has a clinical practice seeing all diseases in hematopoietic cell transplantation, with a clinical research focus on the prevention and treatment of post-transplant complications.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Blood and Marrow Transplantation
- Hematology

ACADEMIC APPOINTMENTS

- Associate Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- "A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies", Cancer Treatment Research Foundation (2005-2009)
- K23-"Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy", NIH (2003-2008)

PROFESSIONAL EDUCATION

- Medical Education: Dartmouth Geisel School of Medicine Office of the Registrar (1991) NH
- Fellowship: Johns Hopkins Hospital (1999) MD
- Residency: Strong Memorial Hospital (1995) NY
- Fellowship: Mount Sinai Medical Center (1998) NY
- Internship: Strong Memorial Hospital (1993) NY
- MS, Stanford University , Epidemiology (2006)

- MD, Dartmouth Medical School

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.

CLINICAL TRIALS

- Bone Marrow Grafting for Leukemia and Lymphoma, Recruiting
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Recruiting
- Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries, Recruiting
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease, Not Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial), Not Recruiting
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease, Not Recruiting
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802), Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies, Not Recruiting
- Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Autologous Stem Cell Rescue for Primary Amyloidosis, Not Recruiting
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801), Not Recruiting
- Chronic GVHD Response Measures Validation, Not Recruiting
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder, Not Recruiting
- Defibrotide for Patients With Hepatic Venous-occlusive Disease: A Treatment IND Study, Not Recruiting
- Defibrotide for the Treatment of Severe Hepatic Venous-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease, Not Recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma, Not Recruiting
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma, Not Recruiting
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma, Not Recruiting
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease, Not Recruiting
- Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation, Not Recruiting
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT), Not Recruiting
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma, Not Recruiting
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML, Not Recruiting

- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201), Not Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Not Recruiting
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD, Not Recruiting
- Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease, Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG, Not Recruiting
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD, Not Recruiting
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders, Not Recruiting
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies, Not Recruiting
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients, Not Recruiting
- Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT, Not Recruiting
- Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant, Not Recruiting
- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease, Not Recruiting
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402), Not Recruiting
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702), Not Recruiting
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease, Not Recruiting
- Targeted Therapy of Bronchiolitis Obliterans Syndrome, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting
- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation, Not Recruiting
- Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Donor-derived MDS/AML in families with germline GATA2 mutation** *BLOOD*
Galera, P., Hsu, A. P., Wang, W., Droll, S., Chen, R., Schwartz, J. R., Klco, J. M., Arai, S., Maese, L., Zerbe, C., Parta, M. J., Young, N. S., Holland, et al
2018; 132 (18): 1994–98
- **Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802** *BLOOD ADVANCES*
Holtan, S. G., DeFor, T. E., Panoskaltis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, et al
2018; 2 (15): 1882–88
- **Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Lee, S. J., Flowers, M. D., Storer, B., Onstad, L., Kurukulasuriya, C., Jagasia, M., Hamilton, B., Chen, G., Cutler, C., Broady, R., Arora, M., Pidala, J., Alousi, et al

2018; 24 (8): 1727–32

- **Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome** *BRITISH JOURNAL OF HAEMATOLOGY*
Kernan, N. A., Grupp, S., Smith, A. R., Arai, S., Triplett, B., Antin, J. H., Lehmann, L., Shore, T., Ho, V. T., Bunin, N., Iacobelli, M., Liang, W., Hume, et al
2018; 181 (6): 816–27
- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
2018; 2 (6): 681–90
- **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**
Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffly, et al
ELSEVIER SCIENCE INC.2018: S145
- **Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials**
Holtan, S. G., Defor, T. E., Howard, A., Pidala, J. A., Levine, J. E., Wu, J., Khera, N., Lee, S. J., Bolanos-Meade, J., Ho, V. T., Alousi, A. M., Inamoto, Y., Chen, et al
ELSEVIER SCIENCE INC.2018: S177–S178
- **Donor Derived MDS/AML in Patients with Germline GATA2 Mutations**
Galera, P., Hsu, A., Wang, W., Schwartz, J. R., Klco, J., Arai, S., Holland, S. M., Hickstein, D., Calvo, K.
NATURE PUBLISHING GROUP.2018: 516–17
- **Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., Beumer, J. H., Qiu, J., Cerda, K., Le, R., Otani, J. M., Liu, H., Ross, et al
2018; 24 (2): 373–80
- **Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Hamilton, B. K., Rybicki, L., Arai, S., Arora, M., Cutler, C. S., Flowers, M. D., Jagasia, M., Martin, P. J., Palmer, J., Pidala, J., Majhail, N. S., Lee, S. J., Khera, et al
2018; 24 (2): 393–99
- **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.** *JAMA dermatology*
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W. K., Kim, Y. H.
2018
- **The Cost of Hematopoietic Stem-Cell Transplantation in the United States** *AMERICAN HEALTH AND DRUG BENEFITS*
Broder, M. S., Quock, T. P., Chang, E., Reddy, S. R., Agarwal-Hashmi, R., Arai, S., Villa, K. F.
2017; 10 (7): 366–73
- **An endpoint associated with clinical benefit after initial treatment for chronic graft-versus-host disease.** *Blood*
Martin, P. J., Storer, B. E., Inamoto, Y., Flowers, M. E., Carpenter, P. A., Pidala, J., Palmer, J., Arora, M., Jagasia, M., Arai, S., Cutler, C., Lee, S. J.
2017
- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
2017; 1 (17): 1347–57
- **Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors** *BLOOD*
Holtan, S. G., Khera, N., Levine, J. E., Chai, X., Storer, B., Liu, H. D., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Flowers, M. E., Cutler, et al
2016; 128 (19): 2350-2358
- **Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease** *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE*
Gomez, A. J., Arai, S., Higgins, J. P., Kambham, N.
2016; 140 (6): 570-577

- **Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.** *Leukemia*
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., Bangs, C. D., Cherry, A. M., Arai, S., Arber, D. A., Zehnder, J. L., Gotlib, J.
2016; 30 (4): 947-950
- **Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium.** *Oral diseases*
Yuan, A., Chai, X., Martins, F., Arai, S., Arora, M., Correa, M. E., Pidala, J., Cutler, C. S., Lee, S. J., Treister, N. S.
2016; 22 (3): 235-240
- **Long-awaited news for hepatic veno-occlusive disease.** *Blood*
Arai, S.
2016; 127 (13): 1630-1631
- **Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.** *Blood*
Richardson, P. G., Riches, M. L., Kernan, N. A., Brochstein, J. A., Mineishi, S., Termuhlen, A. M., Arai, S., Grupp, S. A., Guinan, E. C., Martin, P. L., Steinbach, G., Krishnan, A., Nemecek, et al
2016; 127 (13): 1656-1665
- **Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation*
Arora, M., Cutler, C. S., Jagasia, M. H., Pidala, J., Chai, X., Martin, P. J., Flowers, M. E., Inamoto, Y., Chen, G. L., Wood, W. A., Khera, N., Palmer, J., Duong, et al
2016; 22 (3): 449-455
- **A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.** *Clinical cancer research*
Arai, S., Pidala, J., Pusic, I., Chai, X., Jaglowski, S., Khera, N., Palmer, J., Chen, G. L., Jagasia, M. H., Mayer, S. A., Wood, W. A., Green, M., Hyun, et al
2016; 22 (2): 319-327
- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al
2015; 50 (10): 1286-1292
- **Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study** *LANCET HAEMATOLOGY*
Anderlini, P., Wu, J., Gersten, I., Ewell, M., Tolar, J., Antin, J. H., Adams, R., Arai, S., Eames, G., Horwitz, M. E., McCarty, J., Nakamura, R., Pulsipher, et al
2015; 2 (9): E367-E375
- **Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease** *HAEMATOLOGICA*
Palmer, J., Chai, X., Martin, P. J., Weisdorf, D., Inamoto, Y., Pidala, J., Jagasia, M., Pavletic, S., Cutler, C., Vogelsang, G., Arai, S., Flowers, M. E., Lee, et al
2015; 100 (5): 690-695
- **Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.** *American journal of transplantation*
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., Lafayette, R., Coakley, T., Witteles, R. M.
2015; 15 (3): 650-658
- **National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.** *Biology of blood and marrow transplantation*
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G., Kerr, H., Stratton, P., Duarte, et al
2015; 21 (3): 389-401 e1
- **National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.** *Biology of blood and marrow transplantation*
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G., Kerr, H., Stratton, P., Duarte, et al
2015; 21 (3): 389-401 e1
- **Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.** *Biology of blood and marrow transplantation*

Arai, S., Arora, M., Wang, T., Spellman, S. R., He, W., Couriel, D. R., Urbano-Ispizua, A., Cutler, C. S., Bacigalupo, A. A., Battiwalla, M., Flowers, M. E., Juckett, M. B., Lee, et al

2015; 21 (2): 266-274

- **Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease** *HAEMATOLOGICA*
Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., Pidala, J., Flowers, M. E., Arora, M., Jagasia, M., Arai, S., Chai, X., Pavletic, S. Z., Vogelsang, et al
2014; 99 (10): 1618-1623
- **Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.** *Haematologica*
Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., Pidala, J., Flowers, M. E., Arora, M., Jagasia, M., Arai, S., Chai, X., Pavletic, S. Z., Vogelsang, et al
2014; 99 (10): 1618-1623
- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
2014; 20 (6): 837-843
- **Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease** *ARTHRITIS & RHEUMATOLOGY*
Inamoto, Y., Pidala, J., Chai, X., Kurland, B. F., Weisdorf, D., Flowers, M. E., Palmer, J., Arai, S., Jacobsohn, D., Cutler, C., Jagasia, M., Goldberg, J. D., Martin, et al
2014; 66 (4): 1044-1052
- **Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.** *Biology of blood and marrow transplantation*
Palmer, J., Williams, K., Inamoto, Y., Chai, X., Martin, P. J., Tomas, L. S., Cutler, C., Weisdorf, D., Kurland, B. F., Carpenter, P. A., Pidala, J., Pavletic, S. Z., Wood, et al
2014; 20 (3): 337-344
- **Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis** *HEART RHYTHM*
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., Witteles, R. M.
2014; 11 (1): 158-162
- **Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.** *Science translational medicine*
Weng, W., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.
2013; 5 (214): 214ra171-?
- **Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma** *SCIENCE TRANSLATIONAL MEDICINE*
Weng, W., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.
2013; 5 (214)
- **Comorbidity burden in patients with chronic GVHD** *BONE MARROW TRANSPLANTATION*
Wood, W. A., Chai, X., Weisdorf, D., Martin, P. J., Cutler, C., INAMOTO, Y., WOLFF, D., Pavletic, S. Z., Pidala, J., Palmer, J. M., Arora, M., Arai, S., Jagasia, et al
2013; 48 (11): 1429-1436
- **Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.** *Haematologica*
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S. L., Liedtke, M.
2013; 98 (10): 1593-1599
- **Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium** *BONE MARROW TRANSPLANTATION*
Treister, N., Chai, X., Kurland, B., Pavletic, S., Weisdorf, D., Pidala, J., Palmer, J., Martin, P., INAMOTO, Y., Arora, M., Flowers, M., Jacobsohn, D., Jagasia, et al
2013; 48 (8): 1123-1128
- **The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T. I., Schrier, S. L., Liedtke, M.
2013; 161 (3): 367-372

- **H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., Miklos, D. B.
2013; 110 (8): 3005-3010
- **Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation** *ORTHOPEDICS*
Vashi, N., Avedian, R., Brown, J., Arai, S.
2012; 35 (10): E1556-E1561
- **Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium** *BLOOD*
Jacobsohn, D. A., Kurland, B. F., Pidala, J., Inamoto, Y., Chai, X., Palmer, J. M., Arai, S., Arora, M., Jagasia, M., Cutler, C., Weisdorf, D., Martin, P. J., Pavletic, et al
2012; 120 (13): 2545-2552
- **Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Tolar, J., Deeg, H. J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., Adams, R. H., Ewell, M., Leifer, E. S., Gersten, I. D., Carter, S. L., Horowitz, M. M., Nakamura, et al
2012; 18 (7): 1007-1011
- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaanman, J., Brown, et al
2012; 119 (25): 6145-6154
- **More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., Afghahi, A., Liedtke, M.
2012; 138 (5): 509-511
- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al
2012; 47 (4): 581-588
- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.
2012; 47 (4): 516-521
- **Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Pidala, J., Vogelsang, G., Martin, P., Chai, X., Storer, B., Pavletic, S., Weisdorf, D. J., Jagasia, M., Cutler, C., Palmer, J., Jacobsohn, D., Arai, S., Lee, et al
2012; 97 (3): 451-458
- **Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
2012; 31 (3): 325-331
- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
2011; 17 (11): 1679-1687
- **A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRα antibodies** *BLOOD*
Chen, G. L., Arai, S., Flowers, M. E., Otani, J. M., Qiu, J., Cheng, E. C., McMillan, A., Johnston, L. J., Shizuru, J. A., Miklos, D. B.
2011; 118 (15): 4070-4078

- **Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria** *BLOOD*
Arai, S., Jagasia, M., Storer, B., Chai, X., Pidala, J., Cutler, C., Arora, M., Weisdorf, D. J., Flowers, M. E., Martin, P. J., Palmer, J., Jacobsohn, D., Pavletic, et al
2011; 118 (15): 4242-4249
- **Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants** *HUMAN IMMUNOLOGY*
Pereira, S., Vayntrub, T., Hiraki, D. D., Cherry, A. M., Arai, S., Dvorak, C. C., Grumet, F. C.
2011; 72 (6): 503-509
- **Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M., Ho, D. Y., Arai, S., Johnston, L., Brown, J. M.
2011; 17 (5): 693-702
- **Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium** *BLOOD*
Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., Cutler, C., Jacobsohn, D., Palmer, J., Arai, S., Jagasia, M., Lee, S. J.
2011; 117 (17): 4651-4657
- **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.
2011; 46 (2): 192-199
- **Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., Miklos, D. B.
2010; 150 (5): 637-639
- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
2010; 16 (8): 1145-1154
- **Rituximab in hematopoietic cell transplantation** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Arai, S., Miklos, D. B.
2010; 10 (6): 971-982
- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
2009; 114 (5): 1099-1109
- **High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
Majhail, N. S., Flowers, M. E., Ness, K. K., Jagasia, M., Carpenter, P. A., Arora, M., Arai, S., Johnston, L., Martin, P. J., Baker, K. S., Lee, S. J., Burns, L. J.
2009; 43 (1): 49-54
- **Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial** *CYTOTHERAPY*
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., Klingemann, H.
2008; 10 (6): 625-632
- **A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Kurian, A. W., Newton Thompson, R., Gaw, A. F., Arai, S., Ortiz, R., Garber, A. M.
2007; 25 (6): 634-641
- **Natural killer cells: can they be useful as adoptive immunotherapy for cancer?** *Expert Opin Biol Ther*
Arai S, Klingemann H-G
2005; 5: 163-172

- **Regulation of OX40 gene expression in graft-versus- host disease** *20th International Congress of the Transplantation-Society*
Miura, Y., Thoburn, C. J., Bright, E. C., Arai, S., Hess, A. D.
ELSEVIER SCIENCE INC.2005: 57–61
- **Association of Foxp3 regulatory gene expression and graft-versus-host disease** *Blood*
Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD
2004; 104: 2187-93
- **Role of immunotherapy in stem cell transplantation** *INTERNATIONAL JOURNAL OF HEMATOLOGY*
Arai, S., Klingemann, H. G.
2003; 77 (1): 22-28
- **Poor outcome in steroid refractory GVHD with ATG treatment** *Biol Blood Marrow Transplant*
Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB
2002; 8: 155-60
- **Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings** *BONE MARROW TRANSPLANTATION*
Vogelsang, G. B., Arai, S.
2001; 27 (12): 1255-1262
- **von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy** *The Hematology Journal*
Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM
2001; 2: 292-299
- **Management of graft-versus-host disease** *BLOOD REVIEWS*
Arai, S., Vogelsang, G. B.
2000; 14 (4): 190-204